DiamiR Biosciences Corp. (DIMR)

DiamiR Biosciences was planning to go public, but the IPO was withdrawn on Jul 14, 2025.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)1.32M
Net Income (ttm)-633,740
Shares Out n/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About DIMR

DiamiR Biosciences is a molecular diagnostics company initially focused on the development and commercialization of innovative blood-based tests for detection and monitoring of Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative diseases (NDs). The proprietary technology we developed is based on quantitative analysis of “organ-enriched”, i.e. present at higher concentration in specific organs or tissues, microRNAs in plasma. We believe that the technology can also be applied to diseas... [Read more]

Sector Healthcare
Founded 2009
Employees 5
Stock Exchange NASDAQ
Ticker Symbol DIMR
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Diagnostic test developer DiamiR Biosciences files for a $7 million IPO

DiamiR Biosciences, which is developing blood-based tests for neurodegenerative diseases, filed on Friday with the SEC to raise up to $7 million in an initial public offering.

1 year ago - Renaissance Capital

DiamiR Biosciences IPO Registration Document (S-1)

DiamiR Biosciences has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC